Alfuzosin is an alpha-1 adrenergic antagonist used in the symptomatic management of benign prostatic hypertrophy (BPH). Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.
- Mechanism
- Curator reviewed · 4 references
Alpha(1)-adrenoreceptors are found in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra; their activation may lead to contraction of smooth muscle and urinary symptoms in patients with BPH. Alfuzosin selectively binds to and inhibits alpha(1)-adrenergic receptors in the lower urinary tract. This leads to the relaxation of smooth muscle in both the prostate and bladder neck, resulting in the improvement in urine flow and a reduction of urinary symptoms.
- Primary indication
- Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).Curator reviewed · 1 structured indication
- Formula / weight
- C19H27N5O4 · 389.4488 g/mol (avg)
- First approval
- Canada, 2006 · United States, 2004
- Code names
- SL 77499-10
- Brand names
Resolves to
WNMJYKCGWZFFKR-UHFFFAOYSA-NSMILESCOC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1What you can answer from here — as of September 23, 2026
Which drugs share a target with Alfuzosin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account